Adar Makovski Silverstein
Company: Onconova Therapeutics, Inc.
Job title: Director, Corporate Development
Harnessing Multikinase Inhibitors to Weaponize the Next Generation Against Multiple Cancer Indications 2:30 pm
Discussing the potential to treat multiple cancer indications by targeting multiple MOAs with multi-kinases Introducing narazaciclib (ON123300) – discussing its unique MOA, targeting properties and safety profile through preclinical studies Outlining phase 1 study results to date and the future clinical development pathway of narazacliclibRead more
day: Day One